{"article_title": "Wolters Kluwer Clinical Drug Information Connects Customers to Newly Released ACA FUL Drug Pricing Data", "article_keywords": ["information", "customers", "wolters", "kluwer", "cms", "aca", "drug", "released", "clinical", "pricing", "newly", "data", "ful", "solutions"], "article_url": "http://www.businesswire.com/news/home/20160401005182/en/Wolters-Kluwer-Clinical-Drug-Information-Connects-Customers", "article_text": "HUDSON, Ohio--(BUSINESS WIRE)--The Health division of Wolters Kluwer, a leading global provider of information and point of care solutions for the healthcare industry, announced today that customers can access the newly-released Affordable Care Act Federal Upper Limit drug pricing benchmark, or ACA FUL, through two solutions from its Wolters Kluwer Clinical Drug Information business unit.\n\nThe Medi-Span\u00ae application line from Clinical Drug Information is widely considered the industry leader in providing drug pricing data, attributes, and analysis. Wolters Kluwer Clinical Drug Information is providing ACA FUL data through two Medi-Span offerings:\n\nMedi-Span Federal Government Pricing File \u2013 Database provides the monthly value of ACA FUL, plus the Weighted Average Manufacturer\u2019s Price (AMP), upon which the Centers for Medicare and Medicaid Services (CMS) is basing ACA FUL calculations.\n\n\u2013 Database provides the monthly value of ACA FUL, plus the Weighted Average Manufacturer\u2019s Price (AMP), upon which the Centers for Medicare and Medicaid Services (CMS) is basing ACA FUL calculations. Medi-Span\u00ae Price Rx \u2013 Online drug pricing analysis tool will feature ACA FUL among the many price types included in its Product Information Reports. It will be available for inclusion in Custom Reports at a later date.\n\nPublished by CMS, ACA FUL is based on a new formula detailed in the Affordable Care Act. CMS anticipates it will be used to establish reimbursement for drugs covered under Medicaid. It will eventually replace the long-standing CMS FUL pricing type.\n\n\u201cFor nearly two years, the Clinical Drug Information team has been monitoring development of ACA FUL and preparing for its release so that there would be little to no gap for healthcare professionals and businesses requiring efficient access to the data,\u201d said Denise Basow, MD, President & CEO of Clinical Effectiveness at Wolters Kluwer. \u201cMedi-Span offerings continue to be the standard for timely drug product and pricing data that help drive business processes and intelligence gathering for the nation\u2019s top PBMs, pharmaceutical manufacturers, retail pharmacies, and healthcare organizations.\u201d\n\nAbout Wolters Kluwer\n\nWolters Kluwer N.V. (AEX:WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.\n\nWolters Kluwer reported 2015 annual revenues of \u20ac4.2 billion. The company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries and employs 19,000 people worldwide.\n\nWolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).\n\nWolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and organization, visit http://www.wolterskluwer.com/, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.", "article_metadata": {"description": "With the inclusion of ACA FUL in its Medi-Span line of applications, Wolters Kluwer Clinical Drug Information continues its leadership role in providi", "og": {"image": {"width": 465, "identifier": "http://www.businesswire.com/images/bwlogo_square.png", "type": "image/png", "height": 225}}, "twitter": {"description": "With the inclusion of ACA FUL in its Medi-Span line of applications, Wolters Kluwer Clinical Drug Information continues its leadership role in providi", "title": "Wolters Kluwer Clinical Drug Information Connects Customers to Newly Released ACA FUL Drug Pricing Data", "image": {"src": "http://mms.businesswire.com/media/20160401005182/en/517070/21/WK_CMYK.jpg"}, "site": "@businesswire", "widgets": {"csp": "on"}, "card": "summary_large_image"}, "robots": "noodp,noydir", "DC.date.issued": "2016-04-01", "p": {"domain_verify": "95725e0359a14c2e1ccbd936e10d20d6"}, "viewport": "width=device-width,initial-scale=1"}, "article_summary": "The Medi-Span\u00ae application line from Clinical Drug Information is widely considered the industry leader in providing drug pricing data, attributes, and analysis.\nPublished by CMS, ACA FUL is based on a new formula detailed in the Affordable Care Act.\n\u2013 Database provides the monthly value of ACA FUL, plus the Weighted Average Manufacturer\u2019s Price (AMP), upon which the Centers for Medicare and Medicaid Services (CMS) is basing ACA FUL calculations.\nMedi-Span\u00ae Price Rx \u2013 Online drug pricing analysis tool will feature ACA FUL among the many price types included in its Product Information Reports.\nWolters Kluwer Clinical Drug Information is providing ACA FUL data through two Medi-Span offerings:Medi-Span Federal Government Pricing File \u2013 Database provides the monthly value of ACA FUL, plus the Weighted Average Manufacturer\u2019s Price (AMP), upon which the Centers for Medicare and Medicaid Services (CMS) is basing ACA FUL calculations."}